A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Genentech, Inc.
Exelixis
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
Vividion Therapeutics, Inc.
Alnylam Pharmaceuticals
Sotio Biotech Inc.
Erasca, Inc.
Novartis
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Rondo Therapeutics
Washington University School of Medicine
Washington University School of Medicine
Vividion Therapeutics, Inc.
Eli Lilly and Company
Pfizer
Dana-Farber Cancer Institute
University of California, Irvine
Imugene Limited
M.D. Anderson Cancer Center
Sutro Biopharma, Inc.
Pfizer
Seagen Inc.
Tizona Therapeutics, Inc
Amgen
IDEAYA Biosciences
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
City of Hope Medical Center
Eli Lilly and Company
Seagen Inc.
Novartis
Amgen
Sairopa B.V.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Seattle Children's Hospital
Coherus Oncology, Inc.
Tempest Therapeutics
Valo Therapeutics Oy
Epkin
Bicara Therapeutics
Xencor, Inc.
Incyte Corporation
Cardiff University
Leap Therapeutics, Inc.
Toray Industries, Inc
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc.
DEKA Biosciences